Uncovering Institutional Buying In Barclays plc ADR (NYSE: BCS)

Currently, there are 3.79B common shares owned by the public and among those 3.57B shares have been available to trade.

The company’s stock has a 5-day price change of 0.96% and 18.87% over the past three months. BCS shares are trading 19.92% year to date (YTD), with the 12-month market performance up to 40.62% higher. It has a 12-month low price of $6.23 and touched a high of $9.48 over the same period. BCS has an average intraday trading volume of 16.85 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.45%, 14.67%, and 22.66% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Barclays plc ADR (NYSE: BCS) shares accounts for 4.21% of the company’s 3.79B shares outstanding.

It has a market capitalization of $35.62B and a beta (3y monthly) value of 1.49. The company has a debt-to-equity ratio at 3.07. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.36% over the week and 1.56% over the month.

Analysts forecast that Barclays plc ADR (BCS) will achieve an EPS of $0.54 for the current quarter, $0.36 for the next quarter and $1.74 for 2025. The lowest estimate earnings-per-share for the quarter is $0.54 while analysts give the company a high EPS estimate of $0.54. Earnings per share for the fiscal year are expected to increase by 13.82%, and 21.43% over the next financial year. EPS should shrink at an annualized rate of 2.10% over the next five years, compared to 22.49% over the past 5-year period.

Looking at the support for the BCS, a number of firms have released research notes about the stock. BofA Securities stated their Underperform rating for the stock in a research note on October 26, 2023, with the firm’s price target at $8.77-$7.31. Exane BNP Paribas on their part issued Outperform rating on December 14, 2022.

Most Popular

Related Posts